Glad tidings came recently in terms of supervision of two domestic diabetes drugs. Semaglutide, Novo Nordisk's blockbuster hypoglycemic drug, advanced to the administrative approval stage (acceptance number: JXSS2000005/6) on April 20. Dorzagliatin, Hua Medicine's new diabetes drug, has been accepted with its marketing application by CDE in the past few days.
Semaglutide (Ozempic) is known to be a long-acting GLP-1 receptor agonist developed by Novo Nordisk. Its sales have spiked since its launch with 3.248 billion US dollars in 2020. Furthermore, Novo Nordisk has also made available an oral version of Semaglutide (trade name: Rybelsus).
Dorzagliatin appears to be the world's first dual-acting glucokinase activator under development. It aims mainly to recover the damaged blood glucose homeostasis of patients with type 2 diabetes by fixing the defect of the glucose sensor function of glucokinase. It should be noted that more than 20 GKA drugs have progressed to the clinical research stage since the publication of the pharmacological basis of glucokinase activator (GKA) in 2001, and dorzagliatin seems to be the fastest and the first GKA diabetes treatment drugs submitted for new drug marketing application in the world. If you are searching for Semaglutide, then PharmaSources is your best choice. On PharmaSources, you could find various kinds of medical and surgical supplies. There are numerous surgical supply companies and healthcare supply companies on PharmaSouces. If you want to buy medical nursing supplies, then access to PharmaSouces. You can also find pharmaceutical ingredients there.
Diabetes is found to be a major public health problem next only to cancer and cardiovascular and cerebrovascular diseases. China has the largest number of diabetic patients in the world. The survey data released by BMJ in 2020 showed that, (according to the diagnostic criteria of the American Diabetes Association), total diabetic patients in China are as high as approximately 130 million, of which the awareness rate and the treatment rate of type 2 diabetes was only 43.3% and 49.0% respectively.
A plurality of diabetes drugs (beyond compound preparations) have been endorsed in China, which roughly fall into the following categories. Data from Industrial Securities disclosed the scale of China's diabetes drug market in 2019 was approximately 53.98 billion yuan. Frost&Sullivan forecasts that the annual growth rate of China's hypoglycemic drug market will climax at 18.0% in 2021. Such market will continue to rise steadily from 2021 to 2030 with a slowed rate is expected to expand to 259.2 billion yuan in 2030.
(All Rights Reserved)